Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
$86.47
$0.80(1.09%)
At close: 4:00 PM EST
$86.47
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$65.94 - $87.89
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.50M
Market Cap
$50.22B
Enterprise Value$47.94B
Total Cash (Recent Filing)$2.94B
Total Debt (Recent Filing)$107.10M
Price to Earnings (P/E)47.9
Beta0.64
Next Earnings
Apr 29, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding580,800,000
10 Day Avg. Volume4,162,877
30 Day Avg. Volume4,502,094
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue7.90
Enterprise Value/Gross Profit10.11
Enterprise Value/Ebitda34.45
Forecast
1Y Price Target
$96.88Price Target Upside12.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)2.97
Revenue Forecast (FY)$6.68B
Bulls Say, Bears Say
Bulls Say
New Product Expansion PotentialPlanned introduction of a surgical left atrial appendage closure device could expand the surgical franchise and open a complementary market where existing operating room relationships can be leveraged for incremental sales.
Reimbursement And Guideline TailwindsProgress on clinical guideline support and favorable public commentary around Medicare coverage for broader aortic stenosis populations could enlarge the addressable market for transcatheter valve procedures and ease access barriers.
Revenue Beat And Core Product DemandAnalyst highlights that revenue and core product sales exceeded expectations, driven by strong transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies, indicating sustained underlying demand that supports growth prospects.
Bears Say
Execution And Competition Risk Entering New Surgical MarketPlans to enter the left atrial appendage closure surgical market introduce direct competition with established rivals and increase execution risk around gaining share in a new procedural category.
Margin Pressure From Strategic InvestmentsElevated spending on patient access initiatives and an expanded field salesforce has pressured operating margins and reduced adjusted earnings per share, creating near-term profitability headwinds.
Valuation Sensitivity And Limited UpsideAnalyst notes that anticipated durable revenue and earnings growth appears largely priced into a premium valuation, which could limit upside and make the stock sensitive to any execution shortfalls.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $65.94 and its highest was $87.89 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $50.22B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Apr 29, 2026 which is in 58 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Feb 10, 2026. The company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.618 by -$0.038.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.73.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 580,800,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.58 in its last earnings report, missing expectations of $0.618. Following the earnings report the stock price went up 2.959%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.88 (12.04% Upside)
$96.88 (12.04% Upside)
Blogger Sentiment
Bullish
EW Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.10%
12-Months-Change
Fundamentals
Return on Equity
10.43%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: the company delivered strong top‑line growth (Q4 +11.6%, FY +10.7%), robust TAVR and TMTT momentum, and reiterated confident 2026 guidance (8%–10% sales growth; EPS $2.90–$3.05). Key positives include compelling long‑term clinical evidence, successful product launches (SAPIEN M3, NextGen PASCAL), margin discipline and a healthy balance sheet. Near‑term headwinds are primarily deliberate investments in patient access and field resources (driving higher SG&A), one‑time GAAP charges (GennaValve/litigation), an elevated tax rate in the quarter, and distributor inventory adjustments that modestly impacted surgical sales. Management frames the incremental spending as strategic and expects margin expansion over time. Overall, the positive operational and strategic catalysts outweigh the one‑time and timing‑related negatives.View all EW earnings summariesEW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$96.88
▲(12.04% Upside)
Technical Analysis
Ownership Overview
0.21% Insiders
24.43% Mutual Funds
13.77% Other Institutional Investors
36.88% Public Companies and
Individual Investors